Article References
-
AI Framework Boosts CAR T Cell Therapy Discovery | Mirage News
PHILADELPHIA – Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that firmly centers
-
AI Boosts CAR T Cell Therapy Target Discovery | Mirage News
Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that firmly centers scientists'
-
AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy
-
CAR T targets: AI takes the wheel – Cell Press
-
AI framework helps identify new targets for CAR T cell therapy
-
AI framework helps identify new targets for CAR T cell therapy
-
AI-informed approach to CAR design enhances bi-specific CAR T cells
Discover a computational method from St. Jude that screens theoretical chimeric antigen receptor (CAR) designs & optimizes them, which they validated in vivo.
-
More Effective Bi-Specific CAR T Cells Developed Using AI
The method promises to overcome challenges that plague the effectiveness of bi-specific CAR Ts including poor CAR expression.
-
FDA Approves Personalized Cellular Therapy for Advanced Leukemia
Pioneering CAR T-cell Studies Led to First-ever Cancer Cell and Gene Therapy Approval
-
AI Delivers Rapid, Precise Design of Tumor-Targeting Protein
A new protein designed using AI can precisely recognize a key therapeutic target for cancer.
-
CAR T Cell Therapy | Penn Medicine
Penn Medicine was the first to discover CAR T cell therapy, a form of immunotherapy for blood cancer, and continues to lead the field in research.
-
Using AI to predict patient response to CAR-T cell therapy – YouTube
Margot Jak, MD, University Medical Center Utrecht, Utrecht, The Netherlands, describes a project using artificial intelligence (AI) to analyze PET/CT data from the JULIET trial (NCT02445248) and identify patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) that will respond to CAR-T cell therapy. Early results have shown that this AI model can identify a subgroup of patients at very high risk of poor outcome. Future studies will be needed to clarify whether this AI…
-
Penn Researchers Shorten Manufacturing Time for CAR T Cell …
In a pre-clinical study published in Nature Biomedical Engineering, a team in the Perelman School of Medicine abbreviated this process and generated functional CAR T cells with enhanced anti-tumor potency in just 24 hours.
-
HARNESSING ARTIFICIAL INTELLIGENCE TO ACCELERATE …
Researchers at Penn Medicine have developed an artificial intelligence framework that combines large language models with human scientific expertise to systematically discover new targets for CAR T cell therapy, publishing their findings Wednesday in the journal Cell. miragenews.com miragenews.com sciencedirect.com
The team, led by Daniel Baker, who completed his doctorate at Penn in December 2025 under the mentorship of CAR T cell therapy pioneer Carl June and Zoltan Arany, chair of Physiology at Penn, built what they describe as a “human-in-the-loop” AI system designed to address one of the field’s most persistent bottlenecks: identifying which antigens CAR T cells should be engineered to attack. miragenews.com miragenews.com
A Needle in a Growing Haystack
“Discovering a good CAR target is like trying to find a needle in a haystack, except the haystack keeps growing as more sequencing data becomes available,” Baker said. “We thought this would be a strong use-case for AI because one of the strengths of large language models is the amount of data they can consider. Human experts excel at going deep, while LLMs are good at looking across a broad range of data.” miragenews.com miragenews.com
The framework integrates single-cell RNA sequencing datasets and runs LLM-based simulations to nominate and prioritize potential targets, producing a shortlist for expert biological validation. The approach was designed to be disease-agnostic and compatible with future AI models. sciencedirect.com miragenews.com
From Algorithm to Tumor-Killing Cells
As a proof of concept, the team focused on skin cancer and identified glycoprotein non-metastatic melanoma protein B (GPNMB) as the top candidate. They then engineered CAR T cells targeting GPNMB, which showed robust tumor-killing activity in mouse models of multiple cancer types, including melanoma, leukemia, and colorectal cancer. cell.com linkedin.com miragenews.com miragenews.com
An accompanying Cell commentary noted that GPNMB CAR T treatment led to remission without relapse in xenograft models. cell.com
Expanding Beyond Blood Cancers
While CAR T cell therapy has transformed treatment for several blood cancers since its development at Penn, current FDA-approved versions target antigens widely expressed only in blood malignancies. Extending the therapy to solid tumors has been hampered by the difficulty of finding appropriate targets — a process the researchers say their framework can compress from months of manual work to weeks. x.com miragenews.com miragenews.com
The system was built to allow researchers to apply it across disease types without redesigning the underlying architecture, potentially accelerating CAR T development for cancers and non-cancerous conditions alike. miragenews.com miragenews.com